Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
-
To analyze prognostic factors in patients with a glioblastoma multiforme treated in an academic institute over the last 10 years. ⋯ Despite technical developments in surgery and radiotherapy over the last 10 years, survival of patients with a glioblastoma multiforme has not improved in our institution. The analysis of prognostic factors corresponded well with data from the literature. A short hypofractionated scheme seems to be a more appropriate treatment for patients with intermediate or poor prognosis as compared to a conventional scheme. The benefit in median survival for patients treated with an interstitial boost is partly explained by patient selection. Since there were no long-term survivors with this boost treatment, its clinical value, if there is one, is still limited.